Histone Deacetylase Inhibitor MS-275 Inhibits Neuroblastoma Cell Growth by Inducing Cell Cycle Arrest, Apoptosis, Differentiation and by Targeting its Tumor Stem Cell Population
Objective: MS-275, a phase trialed histone deacetylase inhibitor will be characterized for its ability reduce neuroblastoma (NB) viability and to target the tumor stem cell (TSC) population in neuroblastoma. Methods: Ability of MS-275 to reduce NB growth is characterized using a tumorigenic NB N...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_ca |
| Published: |
2009
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1807/18968 |